LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition by XOMA Royalty ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The ...

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and short-term investments of $56.2M vs. $76.6M as of ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

Additionally, LAVA Therapeutics is on track to initiate Phase 1 trials of LAVA-1266 for acute myeloid leukemia by the end of the year, which could target a range of hematological malignancies.

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody ® platform to develop a portfolio of bispecific gamma-delta T cell engagers for ...

--LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment ...

LAVA Therapeutics NV has a consensus price target of $10.13 based on the ratings of 5 analysts. The high is $28 issued by SVB Leerink on September 27, 2022. The low is $1.5 issued by HC Wainwright ...

LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the ...

Ph.D., chief scientific officer at LAVA, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.